Market Overview
Inhalation Spray
Drugs Market is projected to achieve a value of USD 27,640 Million in 2023,
with a linear behavior in the market growth it is forecasted to achieve a value
of USD 43,230 Million by 2033 with a CAGR of 7.7% during the forecast period
2023-2033.
Inhalation spray
is a small handheld device which helps to inhale medicine through your mouth,
directly to the lungs. Inhalation based drugs are used to direct delivery of
medicament to the lungs in sequence to produce local and immediate effects.
The various
class of drugs use in the Inhalation spray such as Corticosteroids,
Bronchodilators, Antihistamines, Combination drugs which use in the treatments
of allergies, asthma and skin problems. Increasing the prevalence of
respiratory diseases such as COPD and Asthma, rising demand of cost effective
treatments option and acceptance of inhalation spray by patients drives the inhalation
spray drugs market growth.
For Instance, according
to the Global Asthma Report, nearly 330 million people have asthma worldwide
and this number is expected to reach more than 400 million cases by 2025.
Increasing tobacco use, air pollution, and smoking are some of the major causes
leading to rising asthma cases globally.
COVID-19 makes a
significant impact on the Inhalation spray market as one of the major symptoms
of COVID-19 is shortness of breath. For instance, as per the article published
in 2021 by MedComm journal, nasal sprays showed the ability to be an effective
COVID-19 treatment and vaccine option. In the Post pandemic era after relaxing
the lockdown, people still suffering from long term effects such as, shortness
of breathing and other respiratory difficulties.
Market Scope
Report Attributes |
Description |
Market Size in 2022 |
USD 25,490 Million |
Market Forecast in 2033 |
USD 43,230 Million |
CAGR % 2023-2033 |
7.7% |
Base Year |
2022 |
Historic Data |
2016-2022 |
Forecast Period |
2023-2033 |
Report USP |
Production,
Consumption, company share, company heatmap, company production capacity,
growth factors and more |
Growth
Drivers |
Innovations in inhalation spray
technology, including the development of more efficient devices and
formulations Many patients, especially children and the elderly, prefer inhalation sprays over traditional oral medications. Inhalation sprays are non-invasive and can be self-administered, reducing the need for healthcare professionals' intervention. |
Segments Covered |
Type,
Application |
Regional Scope |
North America, Europe, APAC,
South America and Middle East and Africa |
Country Scope |
U.S.; Canada;
U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia;
China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico;
Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies |
Teva Pharmaceuticals Industries
Ltd., Mylan N.V., Akorn, Operating Company LLC, Cipla Inc., Sandoz
International GmBH (Novartis AG), Apotex Inc., Lupin, Viatris Inc., Hikma
Pharmaceuticals PLC, Sun Pharmaceuticals Industries Ltd., Beximco
Pharmaceuticals Ltd., Nephron Pharmaceuticals Corporation |
Market Dynamics
Increasing the
geriatric population coupled with chronic respiratory diseases are expected to
drive the inhalation spray drugs market growth. For instance, the Asthma &
Allergy Foundation of America states that about 7.8% of the U.S. population
aged 65 and older had asthma in 2020.Moreover, key manufacturing player in
market received approval for production of Inhalation spray drugs for the
treatments of respiratory diseases like COPD, asthma.
For instance, Mylan
Pharmaceuticals, a Viatris Inc. subsidiary, received FDA approval for ANDA for
inhalation aerosol Breyna, a generic version of Symbicort indicated for asthma
and COPD patients, in March 2022
Asthma is a non-commutable disease which holds a significant share in the Inhalation spray drug market, which is common in both children and adults. Asthma is a condition that exhibits a higher prevalence among adult females compared to adult males. According to the 2020 report from the Centers for Disease Control and Prevention (CDC), an estimated 25 million individuals in the United States are affected by asthma. Among this population, roughly 20 million are adults aged 18 and above. Furthermore, as per the American Asthma Foundation (AAFA), the year 2021 saw an approximate 25 million individuals grappling with asthma.
Additionally, in 2021, about 5 million children in the United States were
living with asthma. Technological advancement such as smart inhaler, digital
dose counter will improve the effectiveness, convenience and patients
experience in the respiratory disease treatments which fuel the inhalation
spray drugs market growth.
Moreover, the
regulatory obstruction due to rigid laws for the sales in various countries
hamper the market growth. For instance, COFEPRIS, Mexico's regulatory
authority, has introduced fresh guidelines for the approval of generic drugs.
These guidelines exclude the inclusion of patents related to novel therapeutic
applications within their linkage system.
Market Type Analysis
By type, the Inhalation
Spray Drugs market is Categories into Corticosteroids, Bronchodilators,
Antihistamines, Combination Drugs. The Bronchodilators segment accounts for the
largest share of around 43% of the market in 2022.
The rising the
prevalence of asthma and COPD responsible for the market growth. For instance, according
to the World Health Organization (WHO), approximately 262 million individuals
worldwide were afflicted by asthma in 2019. Additionally, the Asthma and
Allergy Foundation of America reported in 2020 that approximately 1 out of
every 13 Americans, totaling nearly 25 million people, were living with asthma.
Therefore, increasing the use of bronchodilator is estimate the market growth.
Market Application Analysis
By Application,
the Inhalation Spray Drugs market is Categories into Hospital Pharmacy, Retail
Pharmacy, Drug Stores, Online Pharmacy. The Retail Pharmacy segment accounts
for the largest share of around 52% of the market in 2022.
Rising
investment in healthcare and increasing Retail facility in developed and
developing country are major factor to drive the segment. For instance, the
average gross margin for drugs in pharmacies is around 43%, indicating a
substantial revenue generation.
The online
pharmacy sector is projected to experience growth in the upcoming forecast
period. Online pharmacies provide patients with convenient and easily
accessible options. As internet usage continues to rise, the volume of
individuals purchasing products from online pharmacies is rapidly expanding.
For instance, in 2020, there was an estimated 45% increase in the quantity of
products dispensed by online pharmacies in England compared to the last year.
Market Regional Analysis
North America
dominate the Inhalation Spray Drugs market with the highest revenue generating
market with share of more than 41%. Well established healthcare facility,
availability of services and products, high expenditure on R&D are the key
driving factor of the region.
For instance, as
per a report from the Canadian government, in 2019, there were 453,700
individuals impacted by chronic obstructive pulmonary disease (COPD), which
constituted 7.2% of the total population. In 2020, this number increased to
488,100 people, accounting for 7.5% of the total population. The rising
prevalence of chronic respiratory conditions in North America has emerged as a
key factor for the increased adoption of inhalational drugs, propel the market
growth.
Europe is
expected to expand the higher growth with highest CAGR in forecasted year. Increasing
investment in healthcare sector, increasing awareness about the respiratory
diseases, emerging new technology, emerging presence of key market players like
Boehringer Ingelheim, Novartis, and Chiesi Group drive the regional growth.
Moreover, Asia-pacific
is the fastest growing Inhalation Spray Drugs market in forecasting year.
Rising prevalence of respiratory diseases, increasing population growth,
government funding for research and healthcare infrastructure are the factors
responsible for growth in forecasted years.
Competitive Analysis
The Inhalation
Spray Drugs market is dominated by a few large companies, such as Teva
Pharmaceuticals Industries Ltd., Mylan N.V., Akorn, Operating Company LLC,
Cipla Inc., Sandoz International GmBH (Novartis AG), Apotex Inc., Lupin,
Viatris Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Industries Ltd.,
Beximco Pharmaceuticals Ltd., Nephron Pharmaceuticals Corporation Others.
There are some
of the key trends that are shaping the competitive landscape of the Inhalation
Spray Drugs market.
August 2022, Lupin
has obtained FDA clearance for Formoterol Fumarate Inhalation Solution, which
is utilized to manage symptoms associated with chronic obstructive pulmonary
disease. The approval from the US Food and Drug Administration (USFDA) pertains
to Lupin's generic edition of Mylan Specialty's Perforomist Inhalation
Solution.
March 2022, Viatris
Inc., in collaboration with Kindeva, has secured its initial FDA endorsement
for a generic adaptation of Symbicort Inhalation Aerosol, known as Breyna
(Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol). This
medication is employed in the continuous management of asthma and chronic obstructive
pulmonary disease (COPD).
In August 2018,
Lily Pharmaceuticals has introduced an intranasal glucagon nasal spray designed
for the emergency treatment of severe hypoglycemia in patients. As reported in
a study presented at ADA 2017, this nasal glucagon demonstrated an estimated
96.0% effectiveness in addressing emergency situations in individuals with type
1 diabetes.
By Type
·
Corticosteroids
·
Bronchodilators
·
Antihistamines
·
Combination Drugs
By Application
·
Hospital Pharmacy
·
Retail Pharmacy
·
Drug Stores
· Online Pharmacy
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
Inhalation Spray Drugs market was valued at USD 25,490 million in 2022 and is estimated to grow at a CAGR of 7.7%.
Major companies operating within the Inhalation Spray Drugs market, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Akorn, Operating Company LLC, Cipla Inc., Sandoz International GmBH (Novartis AG), Apotex Inc., Lupin, Viatris Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Industries Ltd., Beximco Pharmaceuticals Ltd., Nephron Pharmaceuticals Corporation, Others.
North America dominates the market with an active share of 41%, while North America is estimated to grow at a higher CAGR of 3.2%.
Only Three Thousand Four Hundred Ninety Nine US dollar
Only Four Thousand Four Hundred Ninety Nine US dollar
Only Five Thousand Four Hundred Ninety Nine US dollar